Article
A mimic of phosphorylated prolactin induces apoptosis by activating AP‑1 and upregulating p21/waf1 in human prostate cancer PC3 cells
- Authors:
-
View Affiliations / Copyright
Affiliations:
Department of Epidemiology and Health Statistics, School of Public Health and Family Medicine, Capital Medical University, Beijing 100069, P.R. China, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China
-
Pages:
1064-1068
|
Published online on:
August 23, 2012
https://doi.org/10.3892/ol.2012.876
- Expand metrics +
Metrics:
Total
Views: 0
(Spandidos Publications: | PMC Statistics:
)
Metrics:
Total PDF Downloads: 0
(Spandidos Publications: | PMC Statistics:
)
This article is mentioned in:
Abstract
A mimic of phosphorylated prolactin (S179D PRL) has been demonstrated to inhibit prostate cancer cell growth in vitro and in vivo; however, the mechanisms involved in this process remain unknown. In this study, we identified that a four‑day treatment of S179D PRL (1 µg/ml) in human prostate PC3 cancer cells activated JNK, c‑fos and c‑jun, and led to apoptosis. We also demonstrated that p21/waf1 was upregulated in cells transfected with the human PRL receptor (S1b) following a four‑day incubation with S179D PRL (1 µg/ml). Once the cells were cotransfected with S1b and either c‑fos, c‑jun or the c‑fos/c‑jun constructs for 24 h, S17D PRL activated JNK, c‑fos and c‑jun, and induced apoptosis in the c‑fos/c‑jun transfected cells. Additionally, S179D PRL upregulated p21 luciferase activity in the cells transfected with the S1b, activating protein-1 (AP‑1) (7x) Luc or p21 Luc constructs. SP600125 (25 µM), a JNK blocker, inhibited the upregulation of AP‑1 Luc and p21 Luc in the c‑fos/c‑jun transfected cells. These results demonstrate that S179D PRL activates JNK and AP‑1, which leads to p21 upregulation and apoptosis in human prostate PC3 cancer cells.
View References
|
1.
|
W WuE GinsburgBK VonderhaarAM WalkerS179D
prolactin increases vitamin D receptor and p21 through
up-regulation of short 1b prolactin receptor in human prostate
cancer cellsCancer
Res6575097515200510.1158/0008-5472.CAN-04-335016103106
|
|
2.
|
R DasBK VonderhaarTransduction of
prolactins (PRL) growth signal through both long and short forms of
the PRL receptorMol Endocrinol91750175919958614411
|
|
3.
|
N BinartP Imbert-BolloreN BaranC
VigliettaPA KellyA short form of the prolactin (PRL) receptor is
able to rescue mammopoiesis in heterozygous PRL receptor miceMol
Endocrinol1710661074200310.1210/me.2002-018112624115
|
|
4.
|
W WuD CossMY LorensonCB KuoXL XuAM
WalkerDifferent biological effects of unmodified prolactin and a
molecular mimic of phosphorylated prolactin involve different
signaling
pathwaysBiochemistry4275617570200310.1021/bi034217s12809512
|
|
5.
|
JP MengCH Tsai-MorrisML DufauHuman
prolactin receptor variants in breast cancer: Low ratio of short
forms to the long-form human prolactin receptor associated with
mammary carcinomaCancer
Res6456775682200410.1158/0008-5472.CAN-04-101915313907
|
|
6.
|
AM QaziCH Tsai-MorrisML
DufauLigand-independent homo- and heterodimerization of human
prolactin receptor variants: inhibitory action of the short forms
by heterodimerizationMol
Endocrinol2019121923200610.1210/me.2005-029116556730
|
|
7.
|
MT NevalainenEM ValvePM IngletonM NurmiPM
MartikainenPL HarkonenProlactin and prolactin receptors are
expressed and functioning in human prostateJ Clin
Invest99618627199710.1172/JCI1192049045863
|
|
8.
|
X XuE KreyeCB KuoAM WalkerA molecular
mimic of phosphorylated prolactin markedly reduced tumor incidence
and size when DU145 human prostate cancer cells were grown in nude
miceCancer Res61609861042001
|
|
9.
|
W WuL ZanelloAM WalkerS179D prolactin
sensitizes human prostate cancer cells such that physiological
concentrations of 1,25 dihydroxy vitamin D3 result in growth
inhibition and cell
deathProstate6714981506200710.1002/pros.20598
|
|
10.
|
T ChenYS WongSelenocystine induces S-phase
arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by
modulating ERK and Akt phosphorylationJ Agric Food
Chem561057410581200810.1021/jf802125t18959417
|
|
11.
|
EJ LeeGS MoonWS ChoiWJ KimSK
MoonNaringin-induced p21WAF1-mediated G(1)-phase cell cycle arrest
via activation of the Ras/Raf/ERK signaling pathway in vascular
smooth muscle cellsFood Chem
Toxicol4638003807200810.1016/j.fct.2008.10.00218951945
|
|
12.
|
SJ LeeHM KimYH ChoK ParkEJ KimKH
jungAqueous extract of Magnolia officinalis mediates
proliferative capacity, p21WAF1 expression and TNF-alpha-induced
NF-kappaB activity in human urinary bladder cancer 5637 cells;
involvement of p38 MAP kinaseOncol Rep187297362007
|
|
13.
|
I OlazabalJ MunozS OguetaE ObregonJP
Garcia-RuizProlactin (PRL)-PRL receptor system increases cell
proliferation involving JNK (c-jun amino terminal kinase) and AP-1
activation: inhibition by glucocorticoidsMol
Endocrinol14564575200010.1210/mend.14.4.044210770493
|
|
14.
|
KL SchwertfegerS HunterLE HeasleyV
LevresseRP LeonJ DeGregoriSM AndersonProlactin stimulates
activation of c-jun N-terminal kinase (JNK)Mol
Endocrinol1415921602200010.1210/mend.14.10.053611043575
|
|
15.
|
JM GonzalezA Navarro-PucheB CasarP CrespoV
AndresFast regulation of AP-1 activity through interaction of lamin
A/C, ERK1/2, and c-fos at the nuclear envelopeJ Cell
Biol183653666200810.1083/jcb.20080504919015316
|
|
16.
|
M RoyuelaG Rodriguez-BerrigueteB FraileR
PaniaguaTNF-alpha/IL-1/NF-kappaB transduction pathway in human
cancer prostateHistol Histopathol2312791290200818712680
|
|
17.
|
W WuYH ChenE UedaD TanP BartoliniAM
WalkerDifferent forms of prolactin have opposing effects on the
expression of cell cycle regulatory proteins in differentiated
mammary epithelial cellsOncol Res167584200616898268
|
